Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease

In FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk), the proprotein convertase subtilisin-kexin type 9 inhibitor evolocumab reduced low-density lipoprotein cholesterol (LDL-C) and risk of cardiovascular events and was safe and well tolerated ove...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Circulation (New York, N.Y.) N.Y.), 2022-10, Vol.146 (15), p.1109-1119
Hauptverfasser:	O'Donoghue, Michelle L, Giugliano, Robert P, Wiviott, Stephen D, Atar, Dan, Keech, Anthony, Kuder, Julia F, Im, KyungAh, Murphy, Sabina A, Flores-Arredondo, Jose H, López, J Antonio G, Elliott-Davey, Mary, Wang, Bei, Monsalvo, Maria Laura, Abbasi, Siddique, Sabatine, Marc S
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal, Humanized Anticholesteremic Agents - adverse effects Atherosclerosis - chemically induced Atherosclerosis - drug therapy Cardiovascular Diseases - chemically induced Cardiovascular Diseases - drug therapy Cholesterol, LDL Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Myocardial Infarction - epidemiology PCSK9 Inhibitors Proprotein Convertase 9 Stroke - epidemiology Subtilisins - therapeutic use Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!